2011•白血病·淋巴瘤Requires access
Molecular mechanism of bortezomib in mantle cell lymphoma
Bingrui Zhao
Open publisher page 0 citations
Abstract
Mantle cell lymphoma is a distinct subtype of non-Hodgkin lymphoma (NHL) that remains incurable with the shortest survival time. Bortezomib is the first proteasome inhibitor used for the treatment of hematological malignant diseases, such as multiple myeloma and relapse or refractory mantle cell lymphoma (MCL). Investing the mechanism of bortezomib for MCL, including modulation of cell cycle, the influence of cell apoptosis, the disturbance of the MCL microenvironment and the cooperative action with other antineoplastic drugs, is helpful to make the treatment strategy for MCL.
Key words:
Bortezomib; Lymphoma,mantle-cell; Molecular mechanism of action